Sangui Biotech International (Sangui Biotech International) Equity-to-Asset

: -3.98 (As of Mar. 2023)

View and export this data going back to . Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sangui Biotech International's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-0.35 Mil. Sangui Biotech International's Total Assets for the quarter that ended in Mar. 2023 was $0.09 Mil. Therefore, Sangui Biotech International's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was -3.98.

The historical rank and industry rank for Sangui Biotech International's Equity-to-Asset or its related term are showing as below:

SGBI's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Sangui Biotech International Equity-to-Asset Historical Data

The historical data trend for Sangui Biotech International's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Equity-to-Asset

2.66

0.62

-0.66

-1.67

-1.82

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Equity-to-Asset																-1.27	-1.82	-1.63	-3.18	-3.98

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangui Biotech International Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Equity-to-Asset falls into.

Sangui Biotech International Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sangui Biotech International's Equity to Asset Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Equity to Asset (A: Jun. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.239	/	0.131
	=	-1.82

Sangui Biotech International's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.354	/	0.089
	=	-3.98

Sangui Biotech International (OTCPK:SGBI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sangui Biotech International Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines